[Venous thromboembolism in oncologic patients: guidelines for prevention and therapy and areas of uncertainty].
Di Minno
Giovanni
G
Consiglio di Indirizzo e Verifica "Fondazione Pascale", Istituto Nazionale Tumori, Napoli.
Tufano
Antonella
A
D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D011322:Primary Prevention / Q000379:methods; D012107:Research Design; D012307:Risk Factors; D013514:Surgical Procedures, Operative / Q000009:adverse effects; D013923:Thromboembolism / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D016306:Vena Cava Filters; D020246:Venous Thrombosis / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*
D000925:Anticoagulants; D000970:Antineoplastic Agents; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight